In recent years, individuals who have integrated computer science with biology have found it relatively easy to secure funding to transition their innovations into the commercial sector. The proposition was straightforward: access extensive datasets, and machine learning would address longstanding challenges in the discovery, development, and testing of new pharmaceuticals.